According to a survey, a third of UK adults have felt anxious because of concerns about their body image. Whilst body contouring treatments were the second most requested treatments over the last year, with a 450% year-on year growth. There is also a growing inclination towards non-invasive cosmetic treatments and filler treatments increased by 11.7% compared with a decrease in surgical procedures by 0.6%.
It is against this backdrop that a new bio-stimulating dermal filler for the body has been launched by Sinclair Pharma on 1st February 2021. LANLUMA® has been specifically formulated to reshape and contour large areas of the body and can be used to treat the upper arms, hips, thighs, hands, décolletage and buttocks. It can also be used to reduce the signs of cellulite and wrinkles. Lanluma can also be used to add volume to the face to compensate for age-related tissue and bone loss which causes lines and sagging.
Lanluma is made from Poly-l-lactic Acid (PLLA) which has been used in medical products for 30 years and has a strong safety record. The formulation induces collagenasis and fibroblast proliferation by stimulating the body’s inflammatory response. The bio-stimulation helps to restore the skin’s inner structure and shape. The injected filler is absorbed by the body, and then over time the new reshaped appearance emerges. This means the results are not instant, but when they become apparent, they look convincing and realistic.
This taps into the zeitgeist for a more natural appearance - and comes hot on the heels of the findings of research which showed that 41% of people considering cosmetic treatments stated that their top concern was having an unnatural appearance.
Depending on the size of the area to be remedied, 2-4 treatments are performed 4-6 weeks apart contingent on the results from the previous session. Patients compliance is important as they are then asked to massage the area post treatment to bring about the best results. Because the new treatment brings about collagenesis the results last for more than 2 years.
Lanluma is classified as a class III medical device and has obtained the CE Mark. The product is easy to store and easy to use in clinic as the injectable PLLA Powder is reconstituted a dry powder by the addition of sterile water and can be used in as little as ten minutes after dilution.
There are two products in the Lanluma range; V for the hands and face, and X for larger areas of the body.
Lanluma follows the lineage established by medical aesthetics company Sinclair Pharma which also boasts Ellansé®, the first collagen stimulating dermal filler for the face, in its treatment portfolio.
The ideal treatment provider will be an experienced injector with a high level of PLLA expertise who is keen to perform body procedures.
There is a recording of the official Lanluma launch presentation by a number of the European Lanluma faculty members on the HCP page of the new product website - www.lanluma.com - for those who have missed it. The site also features information about training to treat with Lanluma.